Guardant Health reported strong growth as oncology testing revenue rose sharply in the second quarter, boosting overall results. Oncology revenue climbed 38% year over year to $219.1 million, driven by a 63% increase in oncology testing volume, while total quarterly revenue rose 44% to $335 million. The company highlighted FDA approval in June of Guardant360 Liquid CDx as a companion diagnostic for Boehringer Ingelheim’s Hernexeos (zongertinib) in HER2-mutant advanced non-small cell lung cancer. Guardant also cited inclusion of its Shield colorectal screening test in American Cancer Society guideline updates and a coverage expansion by UnitedHealthcare. For the diagnostics market, the update reinforces how regulatory companion-diagnostic wins and payer coverage decisions can quickly translate into volume momentum across both oncology and screening segments.